The successful use of Cytoflavin in the patient with postaveny syndrome
A clinical observation of the use of Cytoflavin according to a two-stage scheme (10.0 ml intravenously drip per 200 ml of 0.9% sodium chloride solution for 10 days, followed by a transition to a tablet form of 2 tablets 2 times/day for 25 days) in a patient with postcovid syndrome with pronounced vegetative and neurocognitive disorders. The effectiveness of therapy was confirmed by an improvement in heart rate variability and a decrease in the severity of depression, anxiety (on the HADS scale) and the level of autonomic dysfunction (on the COMPASS-31 scale). The significant changes in levels of fatigue (on a scale MFI) is not marked. The obtained results can serve as a basis for further research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:123 |
|---|---|
| Enthalten in: |
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova - 123(2023), 7 vom: 01., Seite 108-111 |
| Sprache: |
Russisch |
|---|
| Weiterer Titel: |
Uspeshnoe primenenie Tsitoflavina u patsientki s postkovidnym sindromom |
|---|
| Beteiligte Personen: |
Lemeshevskaia, O I [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.07.2023 Date Revised 27.07.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.17116/jnevro2023123071108 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359908659 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359908659 | ||
| 003 | DE-627 | ||
| 005 | 20231226081859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17116/jnevro2023123071108 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359908659 | ||
| 035 | |a (NLM)37490674 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Lemeshevskaia, O I |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The successful use of Cytoflavin in the patient with postaveny syndrome |
| 246 | 3 | 3 | |a Uspeshnoe primenenie Tsitoflavina u patsientki s postkovidnym sindromom |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2023 | ||
| 500 | |a Date Revised 27.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A clinical observation of the use of Cytoflavin according to a two-stage scheme (10.0 ml intravenously drip per 200 ml of 0.9% sodium chloride solution for 10 days, followed by a transition to a tablet form of 2 tablets 2 times/day for 25 days) in a patient with postcovid syndrome with pronounced vegetative and neurocognitive disorders. The effectiveness of therapy was confirmed by an improvement in heart rate variability and a decrease in the severity of depression, anxiety (on the HADS scale) and the level of autonomic dysfunction (on the COMPASS-31 scale). The significant changes in levels of fatigue (on a scale MFI) is not marked. The obtained results can serve as a basis for further research | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cytoflavin | |
| 650 | 4 | |a dysautonomia | |
| 650 | 4 | |a heart rate variability | |
| 650 | 4 | |a neurocognitive disorders | |
| 650 | 4 | |a postaveny syndrome | |
| 650 | 4 | |a the new coronavirus infection | |
| 650 | 7 | |a cytoflavin |2 NLM | |
| 650 | 7 | |a Niacinamide |2 NLM | |
| 650 | 7 | |a 25X51I8RD4 |2 NLM | |
| 650 | 7 | |a Flavin Mononucleotide |2 NLM | |
| 650 | 7 | |a 7N464URE7E |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Inosine Diphosphate |2 NLM | |
| 650 | 7 | |a 86-04-4 |2 NLM | |
| 650 | 7 | |a Succinates |2 NLM | |
| 700 | 1 | |a Kamaeva, E A |e verfasserin |4 aut | |
| 700 | 1 | |a Lukashenko, M V |e verfasserin |4 aut | |
| 700 | 1 | |a Gavrilova, N Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Soprun, L A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova |d 1997 |g 123(2023), 7 vom: 01., Seite 108-111 |w (DE-627)NLM074605267 |x 1997-7298 |7 nnns |
| 773 | 1 | 8 | |g volume:123 |g year:2023 |g number:7 |g day:01 |g pages:108-111 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.17116/jnevro2023123071108 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 123 |j 2023 |e 7 |b 01 |h 108-111 | ||